当前位置: X-MOL 学术Neurol. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Serum level of lipoprotein-associated phospholipase A2 is a potential biomarker of vertebrobasilar dolichoectasia and its progression to cerebral infarction.
Neurological Sciences ( IF 3.3 ) Pub Date : 2020-07-09 , DOI: 10.1007/s10072-020-04563-7
Yuan Liu 1, 2 , Jinhua Zhu 1 , Xuhui Deng 1 , Zhi Yang 1 , Chunchun Chen 3 , Shuxuan Huang 4 , Lue Chen 5 , Ying Ma 6 , Weifeng Lin 7 , Feiqi Zhu 1, 3
Affiliation  

Background

There are no effective therapies to prevent the occurrence and progression of vertebrobasilar dolichoectasia (VBD). In this study, we investigated the relationship between serum levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) and the occurrence and progression of VBD.

Methods

Sixty (60) cases without VBD and ischemia stroke were considered as Group A, 100 cases with VBD were further divided into Group B (VBD without ischemic stroke, n = 54) and Group C (VBD with first ever acute posterior circulation ischemic stroke, n = 46). Demographic data (such as gender and age) and past medical history (such as hypertension, diabetes, and smoking history) were collected. The levels of serum low-density lipoprotein cholesterol (LDL-C), hypersensitivity C reactive protein (hs-CRP), glycosylated hemoglobin (HbAlc), homocysteine (HCY), uric acid (UA), fibrinogen (Fib), and Lp-PLA2, etc. were measured. Logistic regression analysis was used to assess the related factors of VBD and ischemic stroke secondary to VBD.

Results

Logistic multivariate regression analysis showed that only age and the level of serum Lp-PLA2 were significantly higher in group B than those in group A (P < 0.012, P < 0.001, respectively), however, only the level of serum Lp-PLA2 was significantly higher in group C than those in group B (P < 0.001).

Conclusions

The serum marker Lp-PLA2 is an independent risk factor for the occurrence of VBD and the progression of VBD to posterior circulation ischemic stroke. Whether intervening on atherosclerosis could prevent the occurrence and development of VBD needs to be further studied.



中文翻译:

脂蛋白相关磷脂酶 A2 的血清水平是椎基底动脉扩张及其进展为脑梗死的潜在生物标志物。

背景

没有有效的疗法来预防椎基底动脉扩张症(VBD)的发生和进展。在这项研究中,我们研究了血清脂蛋白相关磷脂酶 A2 (Lp-PLA2) 水平与 VBD 发生和进展之间的关系。

方法

六十(60)例无 VBD 和缺血性卒中被认为是 A 组,100 例有 VBD 进一步分为 B 组(VBD 无缺血性卒中,n  = 54)和 C 组(VBD 首次出现急性后循环缺血性卒中,n  = 46)。收集人口统计学数据(如性别和年龄)和既往病史(如高血压、糖尿病和吸烟史)。血清低密度脂蛋白胆固醇 (LDL-C)、超敏反应 C 反应蛋白 (hs-CRP)、糖基化血红蛋白 (HbAlc)、同型半胱氨酸 (HCY)、尿酸 (UA)、纤维蛋白原 (Fib) 和 Lp- 水平测量PLA2等。采用Logistic回归分析评估VBD和继发于VBD的缺血性脑卒中的相关因素。

结果

Logistic 多元回归分析显示,B 组仅年龄和血清 Lp-PLA2 水平显着高于 A 组(分别为P  < 0.012、P  < 0.001),但仅血清 Lp-PLA2 水平显着高于 A 组(分别为 P < 0.012、P < 0.001)。 C组显着高于B组(P  < 0.001)。

结论

血清标志物 Lp-PLA2 是 VBD 发生和 VBD 进展为后循环缺血性卒中的独立危险因素。干预动脉粥样硬化是否能预防VBD的发生和发展有待进一步研究。

更新日期:2020-07-10
down
wechat
bug